Showing results (1-10 of 310) with videos related to
Sort By:
Pageof 31
Current Topics in Medicinal Chemistry|June 25, 2005
Dual COX-inhibitors: the answer is NO?Stefano Fiorucci, Elisabetta AntonelliInflammation & Allergy Drug Targets|April 15, 2006
NO-NSAIDs: from inflammatory mediators to clinical readoutsStefano Fiorucci, Elisabetta AntonelliCardiovascular Drug Reviews|June 5, 2004
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current statusStefano Fiorucci, Elisabetta Antonelli, Paola Tocchetti, et al.Molecular Pharmacology|May 25, 2005
The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genesGiovanni Rizzo, Barbara Renga, Elisabetta Antonelli, et al.British Journal of Pharmacology|September 4, 2004
Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in miceStefano Fiorucci, Elisabetta Antonelli, Eleonora Distrutti, et al.Hepatology (Baltimore, Md.)|August 19, 2005
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosisStefano Fiorucci, Elisabetta Antonelli, Andrea Mencarelli, et al.Gastroenterology|November 3, 2004
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosisStefano Fiorucci, Elisabetta Antonelli, Giovanni Rizzo, et al.The Journal of Pharmacology and Experimental Therapeutics|June 28, 2005
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosisStefano Fiorucci, Giovanni Rizzo, Elisabetta Antonelli, et al.Hepatology (Baltimore, Md.)|February 10, 2004
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activationStefano Fiorucci, Elisabetta Antonelli, Eleonora Distrutti, et al.Inflammation & Allergy Drug Targets|February 1, 2011
Hydrogen sulfide: from physiology to pharmacologyStefano FiorucciPageof 31